Register a trial

Please note that the ANZCTR website will be unavailable from 1:00pm until 2:00pm (AEST) on Thursday 10th of April for website maintenance. Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.


The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.


With activity expected to increase on the ANZCTR again, there may be extended wait times while we process pending studies, with priority being given to those trials submitted in February. Thank you for your patience.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01802788




Registration number
NCT01802788
Ethics application status
Date submitted
21/02/2013
Date registered
1/03/2013

Titles & IDs
Public title
5 Year Observation of Patients With PORTICO Valves
Scientific title
International Long-term Follow-up Study of Patients Implanted With a Portico™ Valve
Secondary ID [1] 0 0
CV-12-054-EU-PV
Universal Trial Number (UTN)
Trial acronym
PORTICO-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Aortic Valve Stenosis 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Cohort A - Patients implanted with a Portico valve after CE mark

Cohort B - Patients implanted in previous SJM-sponsored premarket studies
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With All-cause Mortality
Assessment method [1] 0 0
Percentage of participants that died for any reason at 1 year post implantation
Timepoint [1] 0 0
1 year post implant
Secondary outcome [1] 0 0
Percentage of Participants With All Cause Mortality in Cohort A
Assessment method [1] 0 0
Percentage of participants that died for any reason at 30 days through 5 years post implantation
Timepoint [1] 0 0
30 days through 5 years post implant
Secondary outcome [2] 0 0
Number of Participants With All-cause Mortality (30 Days, Annually From 1 Year Through 5 Years) in Cohort B
Assessment method [2] 0 0
Number of participants who died for any reason at different time points such as 30 days, 1 year, 2 years, 3 years, 4 years and 5 years.
Timepoint [2] 0 0
30 days through 5 years post implant
Secondary outcome [3] 0 0
Percentage of Participants With Cardiovascular Mortality as Defined by the Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [3] 0 0
Percentage of participants that died for cardiovascular or unknown reasons as defined by VARC-2 at 30 days through 5 years post implantation
Timepoint [3] 0 0
30 days through 5 years post implant
Secondary outcome [4] 0 0
Number of Participants With Cardiovascular Mortality Occurring at Each Time Window (30 Days, 1 Year, 2 Years, 3 Years, 4 Years and 5 Years) in Cohort B
Assessment method [4] 0 0
Number of participants who died for any reason at different time points such as 30 days, 1 year, 2 years, 3 years, 4 years and 5 years.
Timepoint [4] 0 0
30 days through 5 years post implant
Secondary outcome [5] 0 0
Percentage of Participants With Non-Cardiovascular Mortality as Defined by the Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [5] 0 0
Percentage of participants that died for any reason at 30 days through 5 years post implantation
Timepoint [5] 0 0
30 days through 5 years post implant
Secondary outcome [6] 0 0
Number of Participants With Non-Cardiovascular Mortality Occurring at Each Time Window (30 Days, 1 Year, 2 Years, 3 Years, 4 Years and 5 Years) in Cohort B
Assessment method [6] 0 0
Number of participants who died for any reason at different time points such as 30 days, 1 year, 2 years, 3 years, 4 years and 5 years.
Timepoint [6] 0 0
30 days through 5 years post implant
Secondary outcome [7] 0 0
Percentage of Participants With Myocardial Infarction as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [7] 0 0
Percentage of participants with a myocardial infarction as defined by VARC-2 at 30 days through 5 years post implantation post implantation
Timepoint [7] 0 0
30 days through 5 years post implant
Secondary outcome [8] 0 0
Number of Participants With Myocardial Infarction as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [8] 0 0
Number of participants with a myocardial infarction as defined by VARC-2 at 30 days through 5 years post implantation post implantation
Timepoint [8] 0 0
30 days through 5 years post implant
Secondary outcome [9] 0 0
Percentage of Participants With Vascular Access Site Complication as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [9] 0 0
Percentage of participants with vascular access site complication (major or minor) as defined by VARC-2 at 30 days post implantation
Timepoint [9] 0 0
30 days post implant
Secondary outcome [10] 0 0
Percentage of Participants With Bleeding Events as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [10] 0 0
Percentage of participants with a bleeding events (life threatening, major or minor) as defined by VARC-2 at 30 days post implantation
Timepoint [10] 0 0
30 days post implant
Secondary outcome [11] 0 0
Percentage of Participants With Stage 1, 2 and 3 Acute Kidney Injury as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [11] 0 0
Percentage of participants with a Stage 1, 2 or Stage 3 acute kidney injury as defined by VARC-2 at 30 days post implantation
Timepoint [11] 0 0
30 days post implant
Secondary outcome [12] 0 0
Mean Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Aortic Valve Area)
Assessment method [12] 0 0
The aortic valve area as interpreted by an independent echocardiographic core laboratory at 30 days through 5 years post implantation
Timepoint [12] 0 0
30 days through 5 years post implant
Secondary outcome [13] 0 0
Mean Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Mean Transvalvular Gradient)
Assessment method [13] 0 0
The mean transvalvular gradient as interpreted by an independent echocardiographic core laboratory at 30 days through 5 years post implantation
Timepoint [13] 0 0
30 days through 5 years post implant
Secondary outcome [14] 0 0
Number of Participants With New York Heart Association (NYHA) Functional Classification of Heart Failure
Assessment method [14] 0 0
The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity: Class I - No symptoms and no limitation in ordinary physical activity; Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; Class III - Marked limitation in activity due to symptoms; Class IV - Severe limitations.
Timepoint [14] 0 0
30 days post implant
Secondary outcome [15] 0 0
Number of Participants With New York Heart Association (NYHA) Functional Classification of Heart Failure
Assessment method [15] 0 0
The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity: Class I - No symptoms and no limitation in ordinary physical activity; Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; Class III - Marked limitation in activity due to symptoms; Class IV - Severe limitations.
Timepoint [15] 0 0
1 year post implant
Secondary outcome [16] 0 0
Number of Participants With New York Heart Association (NYHA) Functional Classification of Heart Failure
Assessment method [16] 0 0
The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity: Class I - No symptoms and no limitation in ordinary physical activity; Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; Class III - Marked limitation in activity due to symptoms; Class IV - Severe limitations.
Timepoint [16] 0 0
2 years post implant
Secondary outcome [17] 0 0
Number of Participants With New York Heart Association (NYHA) Functional Classification of Heart Failure
Assessment method [17] 0 0
The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity: Class I - No symptoms and no limitation in ordinary physical activity; Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; Class III - Marked limitation in activity due to symptoms; Class IV - Severe limitations.
Timepoint [17] 0 0
3 years post implant
Secondary outcome [18] 0 0
Number of Participants With New York Heart Association (NYHA) Functional Classification of Heart Failure
Assessment method [18] 0 0
The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity: Class I - No symptoms and no limitation in ordinary physical activity; Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; Class III - Marked limitation in activity due to symptoms; Class IV - Severe limitations.
Timepoint [18] 0 0
4 years post implant
Secondary outcome [19] 0 0
Number of Participants With New York Heart Association (NYHA) Functional Classification of Heart Failure
Assessment method [19] 0 0
The New York Heart Association (NYHA) Functional Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity: Class I - No symptoms and no limitation in ordinary physical activity; Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity; Class III - Marked limitation in activity due to symptoms; Class IV - Severe limitations.
Timepoint [19] 0 0
5 years post implant
Secondary outcome [20] 0 0
Mean Six Minute Walk Test (6MWT)
Assessment method [20] 0 0
Distance in metres that the participant can walk in 6 minutes. The six-minute walking test (6MWT) is a commonly used objective measure of functional exercise capacity in individuals with moderately severe impairment.
Timepoint [20] 0 0
30 days through 5 years post implant
Secondary outcome [21] 0 0
Mean Quality of Life Assessment in Cohort A
Assessment method [21] 0 0
EuroQuol-5 Dimensions (EQ5D) is a standardized instrument for use as a measure of health outcome applicable to a wide range of health conditions and treatments. A visual analog scale (VAS) for health is also included in the measure as a patient-reported estimate of overall health status. This scale ranges between 0-100, where 0 is 'the worst health you can imagine' and 100 is 'the best health you can imagine'.
Timepoint [21] 0 0
30 days and 1 year post implant
Secondary outcome [22] 0 0
Percentage of Participants With Transient Ischemic Attack in Cohort A
Assessment method [22] 0 0
Percentage of participants with transient ischemic attack as defined by VARC-2 at 30 days through 5 years post implantation
Timepoint [22] 0 0
30 days through 5 years post implantation
Secondary outcome [23] 0 0
Number of Participants With Transient Ischemic Attack in Cohort B
Assessment method [23] 0 0
Number of participants with transient ischemic attack as defined by VARC-2 at 30 days through 5 years post implantation
Timepoint [23] 0 0
30 days through 5 years post implantation
Secondary outcome [24] 0 0
Percentage of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [24] 0 0
Percentage of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 30 days post implantation
Timepoint [24] 0 0
30 days post implant
Secondary outcome [25] 0 0
Percentage of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [25] 0 0
Percentage of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 1 year post implantation
Timepoint [25] 0 0
1 year post implant
Secondary outcome [26] 0 0
Percentage of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [26] 0 0
Percentage of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 2 years post implantation
Timepoint [26] 0 0
2 years post implant
Secondary outcome [27] 0 0
Percentage of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [27] 0 0
Percentage of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 3 years post implantation
Timepoint [27] 0 0
3 years post implant
Secondary outcome [28] 0 0
Percentage of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [28] 0 0
Percentage of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 4 years post implantation
Timepoint [28] 0 0
4 years post implant
Secondary outcome [29] 0 0
Percentage of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [29] 0 0
Percentage of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 5 years post implantation
Timepoint [29] 0 0
5 years post implant
Secondary outcome [30] 0 0
Number of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [30] 0 0
Number of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 2 years post implantation
Timepoint [30] 0 0
2 years post implant
Secondary outcome [31] 0 0
Number of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [31] 0 0
Number of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 3 years post implantation
Timepoint [31] 0 0
3 years post implant
Secondary outcome [32] 0 0
Number of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [32] 0 0
Number of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 4 years post implantation
Timepoint [32] 0 0
4 years post implant
Secondary outcome [33] 0 0
Number of Participants With Stroke as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [33] 0 0
Number of participants with a stroke (disabling and non-disabling) as defined by VARC-2 at 5 years post implantation
Timepoint [33] 0 0
5 years post implant
Secondary outcome [34] 0 0
Percentage of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [34] 0 0
Percentage of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 30 days post implantation
Timepoint [34] 0 0
30 days post implant
Secondary outcome [35] 0 0
Percentage of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [35] 0 0
Percentage of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 1 year post implantation
Timepoint [35] 0 0
1 year post implant
Secondary outcome [36] 0 0
Percentage of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [36] 0 0
Percentage of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 2 years post implantation
Timepoint [36] 0 0
2 years post implant
Secondary outcome [37] 0 0
Percentage of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [37] 0 0
Percentage of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 3 years post implantation
Timepoint [37] 0 0
3 years post implant
Secondary outcome [38] 0 0
Percentage of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [38] 0 0
Percentage of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 4 years post implantation
Timepoint [38] 0 0
4 years post implant
Secondary outcome [39] 0 0
Percentage of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort A
Assessment method [39] 0 0
Percentage of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 5 years post implantation
Timepoint [39] 0 0
5 years post implant
Secondary outcome [40] 0 0
Number of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [40] 0 0
Number of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 2 years post implantation
Timepoint [40] 0 0
2 years post implant
Secondary outcome [41] 0 0
Number of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [41] 0 0
Number of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 3 years post implantation
Timepoint [41] 0 0
3 years post implant
Secondary outcome [42] 0 0
Number of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [42] 0 0
Number of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 4 years post implantation
Timepoint [42] 0 0
4 years post implant
Secondary outcome [43] 0 0
Number of Participants With Conduction Disturbances and Cardiac Arrythmias as Defined by Valve Academic Research Consortium-2 (VARC-2) in Cohort B
Assessment method [43] 0 0
Number of participants with a conduction disturbances and cardiac arrhythmias as defined by VARC-2 at 5 years post implantation
Timepoint [43] 0 0
5 years post implant
Secondary outcome [44] 0 0
Percentage of Participants With Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Paravalvular Aortic Regurgitation) in Cohort A
Assessment method [44] 0 0
Percentage of participants with a paravalvular aortic regurgitation as defined by VARC-2 at 30 days post implantation
Timepoint [44] 0 0
30 days post implant
Secondary outcome [45] 0 0
Percentage of Participants With Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Paravalvular Aortic Regurgitation) in Cohort A
Assessment method [45] 0 0
Percentage of participants with a paravalvular aortic regurgitation as defined by VARC-2 at 1 year post implantation
Timepoint [45] 0 0
1 year post implant
Secondary outcome [46] 0 0
Percentage of Participants With Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Paravalvular Aortic Regurgitation)
Assessment method [46] 0 0
Percentage of participants with a paravalvular aortic regurgitation as defined by VARC-2 at 2 years post implantation
Timepoint [46] 0 0
2 years post implant
Secondary outcome [47] 0 0
Percentage of Participants With Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Paravalvular Aortic Regurgitation)
Assessment method [47] 0 0
Percentage of participants with a paravalvular aortic regurgitation as defined by VARC-2 at 3 years post implantation
Timepoint [47] 0 0
3 years post implant
Secondary outcome [48] 0 0
Percentage of Participants With Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Paravalvular Aortic Regurgitation)
Assessment method [48] 0 0
Percentage of participants with a paravalvular aortic regurgitation as defined by VARC-2 at 4 years post implantation
Timepoint [48] 0 0
4 years post implant
Secondary outcome [49] 0 0
Percentage of Participants With Prosthetic Valve Function as Defined by Valve Academic Research Consortium-2 (VARC-2) (Paravalvular Aortic Regurgitation)
Assessment method [49] 0 0
Percentage of participants with a paravalvular aortic regurgitation as defined by VARC-2 at 5 years post implantation
Timepoint [49] 0 0
5 years post implant

Eligibility
Key inclusion criteria
* Patient has signed the Patient Informed Consent prior to participating in the clinical investigation.
* Patient has been referred for a Portico Valve implant as per Heart Team decision or patient has received a Portico Valve as per participation in an SJM sponsored regulatory or first-in-human trial.
* Patient has senile degenerative aortic valve stenosis confirmed by echocardiographically derived criteria*:

* An initial aortic valve area (AVA) of less than or equal to (=) 1.0 cm2 (or indexed EOA less than or equal to (=) 0.6 cm2/m2) AND
* A mean gradient greater than (>)40 mmHg or jet velocity greater than (>)4.0 m/s or Doppler Velocity Index less than (<)0.25. If the mean gradient is <40 mmHg and left ventricular ejection fraction (LVEF) <55%, then the site may as well perform a dobutamine stress echo to see if the mean gradient increases to >40 mmHg." (Baseline measurement taken by echo within 6 months of index procedure.)
* Patient has a life expectancy more than (>) 12 months.

For patients enrolled in a French site:

* Patient is at high risk for surgery as demonstrated by a Logistic EuroSCORE equal or more than (=) 20 and/or a Society of Thoracic Surgeon (STS) mortality risk score of more than (>) 10% and/or by clinical judgment of the Heart Team based on the individual risk profile (comorbidities).

* Not applicable for a patient who has received a Portico Valve as per participation in an SJM sponsored Regulatory or First-In-Human trial.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any case in which the Portico Valve would not be indicated for the patient as per current instructions for use (i.e any "off-label" use).
* Patient has any other aortic valve than tricuspid one.
* Patient has a prosthetic valve or ring in the aortic position.
* Patient needs a concomitant structural heart procedure..
* Patient needs the usage of an embolic protection device.
* Patient is unwilling or unable to comply with all clinical investigation-required follow-up evaluations.
* Patient is pregnant

Study design
Purpose
Duration
Selection
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/04/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/10/2022
Sample size
Target
Accrual to date
Final
1032
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
St Andrews Hospital - Adelaide
Recruitment hospital [3] 0 0
Heart Care Partners-Wesley Hospital - Auchenflower
Recruitment hospital [4] 0 0
The Prince Charles Hospital - Chermside
Recruitment hospital [5] 0 0
Royal North Shore hospital - Leonards Hill
Recruitment hospital [6] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [7] 0 0
Royal Melbourne Hospital - City Campus - Parkville
Recruitment hospital [8] 0 0
Fiona Stanley Hospital - Perth
Recruitment hospital [9] 0 0
North Shore Private Hospital - St Leonards
Recruitment hospital [10] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Auchenflower
Recruitment postcode(s) [3] 0 0
- Chermside
Recruitment postcode(s) [4] 0 0
- Leonards Hill
Recruitment postcode(s) [5] 0 0
- Melbourne
Recruitment postcode(s) [6] 0 0
- Parkville
Recruitment postcode(s) [7] 0 0
- Perth
Recruitment postcode(s) [8] 0 0
- St Leonards
Recruitment postcode(s) [9] 0 0
- Woolloongabba
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Antwerp
Country [2] 0 0
Belgium
State/province [2] 0 0
Bruxelles
Country [3] 0 0
Belgium
State/province [3] 0 0
Liege
Country [4] 0 0
Canada
State/province [4] 0 0
Calgary
Country [5] 0 0
Canada
State/province [5] 0 0
Halifax
Country [6] 0 0
Canada
State/province [6] 0 0
Montreal
Country [7] 0 0
Canada
State/province [7] 0 0
Ottawa
Country [8] 0 0
Canada
State/province [8] 0 0
Quebec
Country [9] 0 0
Canada
State/province [9] 0 0
Saint John
Country [10] 0 0
Canada
State/province [10] 0 0
Toronto
Country [11] 0 0
Canada
State/province [11] 0 0
Vancouver
Country [12] 0 0
Denmark
State/province [12] 0 0
Copenhagen
Country [13] 0 0
France
State/province [13] 0 0
Rennes
Country [14] 0 0
France
State/province [14] 0 0
Toulouse
Country [15] 0 0
Germany
State/province [15] 0 0
Bad Nauheim
Country [16] 0 0
Germany
State/province [16] 0 0
Berlin
Country [17] 0 0
Germany
State/province [17] 0 0
Bernau
Country [18] 0 0
Germany
State/province [18] 0 0
Dortmund
Country [19] 0 0
Germany
State/province [19] 0 0
Dresden
Country [20] 0 0
Germany
State/province [20] 0 0
Frankfurt
Country [21] 0 0
Germany
State/province [21] 0 0
Göttingen
Country [22] 0 0
Germany
State/province [22] 0 0
Hamburg
Country [23] 0 0
Germany
State/province [23] 0 0
Jena
Country [24] 0 0
Germany
State/province [24] 0 0
Karlsruhe
Country [25] 0 0
Germany
State/province [25] 0 0
Leipzig
Country [26] 0 0
Germany
State/province [26] 0 0
Munchen
Country [27] 0 0
Israel
State/province [27] 0 0
Re?ovot
Country [28] 0 0
Italy
State/province [28] 0 0
Alessandria
Country [29] 0 0
Italy
State/province [29] 0 0
Catania
Country [30] 0 0
Italy
State/province [30] 0 0
Massa
Country [31] 0 0
Italy
State/province [31] 0 0
Milano
Country [32] 0 0
Italy
State/province [32] 0 0
Milan
Country [33] 0 0
Italy
State/province [33] 0 0
Monza
Country [34] 0 0
Lithuania
State/province [34] 0 0
Vilnius
Country [35] 0 0
Netherlands
State/province [35] 0 0
Amsterdam
Country [36] 0 0
Netherlands
State/province [36] 0 0
Leeuwarden
Country [37] 0 0
Spain
State/province [37] 0 0
Barcelona
Country [38] 0 0
Spain
State/province [38] 0 0
El Palmar
Country [39] 0 0
Spain
State/province [39] 0 0
Sevilla
Country [40] 0 0
Switzerland
State/province [40] 0 0
Zurich
Country [41] 0 0
United Kingdom
State/province [41] 0 0
Belfast
Country [42] 0 0
United Kingdom
State/province [42] 0 0
Brighton
Country [43] 0 0
United Kingdom
State/province [43] 0 0
London
Country [44] 0 0
United Kingdom
State/province [44] 0 0
Morriston

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Abbott Medical Devices
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Francesco Maisano, MD
Address 0 0
San Raffaele Hospital
Country 0 0
Phone 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

TypeOther DetailsAttachment
Study protocol Study Protocol and Statistical Analysis Plan
Statistical analysis plan Study Protocol and Statistical Analysis Plan



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT01802788